-
公开(公告)号:US07579451B2
公开(公告)日:2009-08-25
申请号:US11186915
申请日:2005-07-21
CPC分类号: C07H21/00 , A61K31/7115 , C07F9/65515 , C07F9/65586 , C07F9/6561 , C07H21/02 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/395 , Y02A50/411 , Y02A50/463 , Y02A50/465 , Y02A50/467
摘要: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-natural nucleobase. In a preferred embodiment, the non-natural nucleobase is difluorotolyl. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.
摘要翻译: 本发明的一个方面涉及包含至少一种非天然核碱基的双链寡核苷酸。 在某些实施方案中,非天然核碱基是二氟苯甲酰基,硝基吲哚基,硝基吡咯基或硝基咪唑基。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链中只有一条含有非天然核碱基。 在某些实施方案中,包含双链寡核苷酸的两条寡核苷酸链都独立地含有非天然核碱基。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一种非天然核碱基的单链寡核苷酸。 在优选的实施方案中,非天然核碱基是二氟苯甲酰基。 在某些实施方案中,在核苷中天然存在的核糖部分被己糖,多环杂烷基环或环己烯基取代。 在某些实施方案中,寡核苷酸中的至少一个磷酸键被硫代磷酸酯键取代。
-
公开(公告)号:US09290760B2
公开(公告)日:2016-03-22
申请号:US13822441
申请日:2011-09-14
申请人: Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
发明人: Kallanthottathil G. Rajeev , Tracy Zimmermann , Muthiah Manoharan , Martin Maier , Kevin Fitzgerald
IPC分类号: C12N15/113 , C12N15/11
CPC分类号: C12N15/113 , C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/322 , C12N2310/343 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , C12N2320/52 , C12N2310/3533
摘要: The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.
摘要翻译: 本发明提供了与至少一种配体缀合的RNA试剂的有效基序,其有利于iRNA双链体的体内递送。 此外,本发明提供了制备这些组合物的方法,以及使用这些组合物将这些iRNA双链体引入细胞的方法,例如用于治疗各种疾病状况。
-
公开(公告)号:US09012498B2
公开(公告)日:2015-04-21
申请号:US13153200
申请日:2011-06-03
申请人: Muthiah Manoharan , Martin Maier , Muthusamy Jayaraman , Shigeo Matsuda , Narayanannair K. Jayaprakash , Kallanthottathil G. Rajeev , Akin Akinc , Thomas A. Baillie
发明人: Muthiah Manoharan , Martin Maier , Muthusamy Jayaraman , Shigeo Matsuda , Narayanannair K. Jayaprakash , Kallanthottathil G. Rajeev , Akin Akinc , Thomas A. Baillie
IPC分类号: A61K31/265 , A61K31/13 , C07C229/00 , C07C229/12 , C12N15/88
CPC分类号: C07C229/12 , A61K31/713 , A61K39/0005 , A61K47/44 , C12N15/113 , C12N15/88 , C12N2310/14 , C12N2320/30
摘要: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
摘要翻译: 本发明涉及一种阳离子脂质,其具有位于阳离子脂质的脂质部分(例如,疏水链)的中间或远端部分中的一个或多个可生物降解基团。 这些阳离子脂质可以掺入用于递送活性剂(例如核酸)的脂质颗粒中。 本发明还涉及包含中性脂质,能够减少聚集的脂质,本发明的阳离子脂质和任选的固醇的脂质颗粒。 脂质颗粒可以进一步包括治疗剂如核酸。
-
公开(公告)号:US08883202B2
公开(公告)日:2014-11-11
申请号:US13318600
申请日:2010-05-05
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Michael E. Jung
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Michael E. Jung
CPC分类号: A61K47/22 , A61K9/1272 , C07D295/13 , C12N15/113 , C12N15/1137 , C12N2310/14 , Y02A50/463
摘要: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).
摘要翻译: 本文公开了包含式(I)的阳离子脂质,中性脂质,固醇和PEG或PEG修饰的脂质的脂质组合物,其中式(I)是(F)。 还公开了制备式(I)的阳离子脂质的方法。
-
公开(公告)号:US08802644B2
公开(公告)日:2014-08-12
申请号:US13357856
申请日:2012-01-25
申请人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号: C12N15/113 , C07C229/06 , A61K47/12 , A61K47/14
CPC分类号: A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于式I的阳离子脂质,包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US08722082B2
公开(公告)日:2014-05-13
申请号:US13128363
申请日:2009-11-10
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Jayaprakash K. Narayanannair , Marco A. Ciufolini
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , David Butler , Jayaprakash K. Narayanannair , Marco A. Ciufolini
CPC分类号: A61K31/7088 , A61K9/1272 , A61K31/7105 , A61K39/00 , A61K2039/55561 , A61K2039/6018 , C12N15/111 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2320/32 , C12N2310/3521 , C12N2310/3533
摘要: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.
摘要翻译: 本发明提供有利地用于脂质颗粒以用于体内递送治疗剂至细胞的脂质。 特别地,本发明提供具有以下结构XIV或XVII的脂质。
-
公开(公告)号:US20130323836A1
公开(公告)日:2013-12-05
申请号:US13696796
申请日:2011-04-22
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Ivan Zlatev , Eric E. Swayze , Thazha P. Prakash , Walter F. Lima
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Ivan Zlatev , Eric E. Swayze , Thazha P. Prakash , Walter F. Lima
IPC分类号: C07H17/02 , C12N15/113
CPC分类号: C07H17/02 , C07H19/067 , C07H21/02 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/3521 , C12N2310/3525
摘要: The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
摘要翻译: 本发明提供式(1)的化合物。 本发明的另一方面涉及一种抑制基因表达的方法,所述方法包括(a)使本发明的寡核苷酸与细胞接触; 和(b)将来自步骤(a)的细胞维持足以获得靶基因的mRNA降解的时间。
-
公开(公告)号:US20130236968A1
公开(公告)日:2013-09-12
申请号:US13805991
申请日:2011-06-20
IPC分类号: C12N15/113 , C08F222/38 , C08F224/00 , C08F228/06 , C08F226/06
CPC分类号: C12N15/113 , A61K47/58 , C08F220/58 , C08F2220/603
摘要: The present invention relates to multifunctional polymers represented by the following formula: The invention further provides methods for their preparation and methods for site-specific delivery of nucleic acids by combining them with targeting ligands, endosomolytic ligands and/or PK modulator ligands.
摘要翻译: 本发明涉及由下式表示的多官能聚合物:本发明进一步提供了它们的制备方法和通过将其与靶配体,内体分解配体和/或PK调节剂配体组合来进行核酸的位点特异性递送的方法。
-
公开(公告)号:US08507661B2
公开(公告)日:2013-08-13
申请号:US12714298
申请日:2010-02-26
CPC分类号: C12N15/111 , A61K47/554 , C12N2310/14 , C12N2310/323 , C12N2310/344 , C12N2310/3515 , C12N2320/51
摘要: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
摘要翻译: 本发明涉及iRNA试剂,其优选包括其中核糖部分被除核糖以外的部分替代的单体。 包含这样的单体可以允许调节掺入其中的iRNA试剂的性质,例如通过使用非核糖部分作为配体或其它实体例如亲油部分的点。 例如胆固醇是直接或间接的系链。 本发明还涉及制备和使用这种修饰的iRNA试剂的方法。
-
公开(公告)号:US20130203836A1
公开(公告)日:2013-08-08
申请号:US13638891
申请日:2011-03-31
IPC分类号: C12N15/113 , C07H19/16 , A61K48/00 , C07H19/06
CPC分类号: C12N15/113 , A61K48/00 , C07H19/06 , C07H19/067 , C07H19/16
摘要: The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2):Formula (1) and Formula (2). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
摘要翻译: 本发明提供式(1)的核苷和至少包含式(2)核苷的寡核苷酸:式(1)和式(2)。 本发明的另一方面涉及一种抑制基因表达的方法,所述方法包括(a)使本发明的寡核苷酸与细胞接触; 和(b)将来自步骤(a)的细胞维持足以获得靶基因的mRNA降解的时间。
-
-
-
-
-
-
-
-
-